A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of flexible-dose paliperidone ER [extended-release] in the treatment of patients with schizoaffective disorder

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of flexible-dose paliperidone ER [extended-release] in the treatment of patients with schizoaffective disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizoaffective disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 Jan 2011 Janssen Cilag reports that the European Union has approved paliperidone extended-release for the treatment of schizoaffective disorder based on the results of this study.
    • 31 Jul 2009 Janssen Pharmaceuticals reports that the US FDA has approved paliperidone extended-release for the treatment of schizoaffective disorder based on the results of this study.
    • 14 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top